Statistical Testing

Ryan Miller

- In the early 1950s the US experienced an outbreak of polio that reached 58,000 new cases in 1952
- Several vaccines had been developed, with one created by Jonas Salk seeming particularly promising. How might the effectiveness of Salk's vaccine be established?
- In 1954, the US Public Health Service organized a large study involving nearly 1 million children in grades 1, 2, and 3, the most vulnerable age groups for polio
 - Do you have any concerns with performing a randomized experiment in this setting?

- Parents must provide consent for their children to receive the vaccination
 - But is it ethical to deliberately leave some of these consenting children unvaccinated?
- A more ethical design might be to offer the vaccine to all consenting children and use those whose parents refused the vaccine as the control group
- Do you have any problems with the aforementioned ethical design?

- Higher-income parents tended to be more likely to consent, and their children tended to be more likely to contract polio
 - This is thought to be because children from poorer backgrounds are more likely to come into contact with mild cases of polio during early childhood when they are protected by antibodies from their mothers
- Thus, family background would be a major source of confounding in the ethical design
 - Any observed differences could be due to this factor and not the efficacy of the vaccine

Polio Epidemic - Randomization and Blinding

- To avoid confounding, the treatment and control groups needed to be randomly selected from the same population: children whose parents consented to treatment
- This meant that some children whose parents consented would be randomly chosen to not receive the vaccine
- Additionally, the Salk vaccine trial included a placebo and was double-blinded
 - Children in the control group received an injection of a saline solution
 - Neither the child, their parents, nor their doctors knew who had received vaccine and who had received placebo

Polio Epidemic - Salk Vaccine Trial Results

The incidence of polio was lower in the treatment group. But to attribute this decrease to the vaccine all other explanations must be ruled out...

Group	n	Polio Cases	Rate per 100,000
Treatment	200000	56	28
Control	200000	142	71
Refused Consent	350000	161	46

- Confounding? No, proper randomization was used
- Sampling bias? No, both groups were randomly chosen from the same population
- Diagnostic bias? No, the doctors and participants were blinded
- Random chance? ...

Statistical Testing

- In the Salk Vaccine Trial, the incidence of polio was reduced by a factor of roughly 2.5 (71/28)
 - But this is only what happened in the sample, we really want to generalize these findings to a broader population
- It is unlikely that the broader population will see a reduction of exactly 2.5, so how can we determine whether the results seen in this sample are convincing evidence that the population will benefit from the vaccine?
- We might be able to use confidence intervals, but instead we'll ask the more direct question:

Had the vaccine made no difference, how likely would be for the vaccinated group to have a 2.5 times lower incidence rate?

Statistical Testing

- This hypothetical scenario: "What if the vaccine made no difference" describes a null hypothesis
 - Statistically speaking, it implies that both population parameters (the polio incidence rates for vaccinated and unvaccinated children) are identical, and any differences we observed in the sample are due to random chance.
- In statistical notation:

Null Hypothesis (H_0) : $\mu_{trt} = \mu_{ctrl}$ or $\mu_{trt} - \mu_{ctrl} = 0$ or $\frac{\mu_{trt}}{\mu_{ctrl}} = 1$

The goal of statistical testing is to use the data observed in a sample to evaluate whether a null hypothesis is plausible

Statistical tests focus finding: The probability of seeing results at least as extreme as those observed in our sample if the null hypothesis were true

- This probability is called the p-value
- The smaller the *p*-value, the stronger the evidence is against the null hypothesis
 - A p-value of 0.01 indicates that if the null hypothesis were true, only 1/100 samples would be expected to produce an outcome as or more extreme as the one we observed in our sample

The Null Distribution

- The way we calculate p-values is similar to the logic underlying confidence intervals
- Interval estimation was based around finding plausible values of a statistic that could occur when repeatedly sampling
- Statistical testing seeks to find plausible values of a statistic that could occur when repeatedly sampling if the null hypothesis were true
- Thus, the sampling distribution in the hypothetical world where the null hypothesis is true is called the null distribution
- The null distribution is centered at the value specified in the null hypothesis, and it displays the distribution of possible sample estimates we would expect to see if the null hypothesis were true

The Null Distribution

In the polio example, here is the null distribution for the factor by which polio was reduced.



The actual experiment showed a reduction of \sim 2.5, what do you think the *p*-value is?

Null and Alternative Hypotheses

Generally, we will pair a null hypothesis with an **alternative hypothesis** that we'd like to establish:

Null Hypothesis (H_0) : $\mu_{trt} = \mu_{ctrl}$ Alternative Hypothesis (H_a) : $\mu_{trt} < \mu_{ctrl}$

- The alternative hypothesis offers a sensible conclusion if our data suggests the null hypothesis is unlikely
 - It also helps us formalize the meaning of "at least as extreme" in our definition of the *p*-value
- We'll first look at one-sided hypothesis tests because they are easy to understand, but most real analyses will use two-sided tests

The TV show Mythbusters uses experiments to evaluate popular beliefs that might not be true. One myth the show investigates is whether yawning is contagious.

- 50 people were recruited with the premise that they were looking for people to appear on the show
- The recruiter met with each person in a small room and either intentionally yawned or did not yawn during the interview
- After the recruiter left, each subject was alone in the room for a period of time while being recorded on video
- Whether or not each subject yawned at any point during or after the interview was recorded
 - When the recruiter didn't yawn, 4 of 16 subjects also yawned
 - ▶ When the recruiter yawned, 10 of 34 subjects also yawned

Hypothesis Testing - Example

With your group:

1. Using the information given regarding this experiment, come up with suitable null and alternative hypotheses

Null Distribution

- 2. Report your estimate of the statistic your test will use
- 3. Estimate the *p*-value using the null distribution below



Hypothesis Testing - Example (Solution)

- 1. $H_0: p_{y|yawn} = p_{y|no \; yawn}$ and $H_A: p_{y|yawn} > p_{y|no \; yawn}$
- 2. The observed difference in proportions is

$$\hat{p}_{y| ext{yawn}} - \hat{p}_{y| ext{no yawn}} = 0.044$$

3. A really large portion of the histogram is more extreme in favor of the alternative than our estimate of 0.044, so the *p*-value is likely around 0.4

We conclude that this experiment does not provide any conclusive evidence that yawning is contagious

Hypothesis Testing - The Alternative Hypothesis

- Suppose we setup an alternative hypothesis stating that the interviewer yawning would make a participant *less likely* to yawn, or H_A: p_{y|yawn} < p_{y|no yawn}
- How would the *p*-value change? (Hint: think about what an "extreme", or unexpected, result looks like here)

Null Distribution



- When the alternative hypothesis is specified in the wrong direction (relative to effect seen in the data) a large fraction of the null distribution is "at least as extreme" as the observed estimate
- In this example, where H_A: p_{y|yawn} < p_{y|no yawn}, the one-sided p-value would be around 0.6
 - Notice this is the compliment of the one-sided p-value for the alternative hypothesis H_A: p_{y|yawn} > p_{y|no yawn}

Statistical Significance

Ronald Fisher, creator of the *p*-value, and described by his peers as "a genius who almost single-handedly created the foundations of modern statistical science", suggests the following guidelines:

p-value	Evidence against the null	
0.100	Borderline	
0.050	Moderate	
0.025	Substantial	
0.010	Strong	
0.001	Overwhelming	

- Generally, modern science uses 0.05 as a threshold for rejecting the null hypothesis
- Given this threshold, p-values < 0.05 are described as "statistically significant"

Statistical Significance

- p < 0.05 is an arbitrary cutoff that shouldn't distract you from the main idea behind p-values
- A p-value of 0.0001 doesn't tell you the same thing as a p-value of 0.04, even though both are "statistically significant"
- When reporting results you should always include the *p*-value itself, not just whether or not it was below the 0.05 threshold for significance
 - Imagine your weather app only telling you: "it's cold" or "it's not cold"
 - Because "Cold" is subjective, it's better to know the temperature and decide for yourself

p-value Misconceptions

- p-values have been much maligned over the last several years, so much so that the largest professional organization of statisticians, the American Statistical Association (ASA), recently issued a statement on p-values
- The statement addresses several different *p*-value misconceptions, the proliferation of these mistakes has led some to abandon *p*-values entirely (They've been banned from the journal: *Basic and Applied Psychology*)

p-value Misconceptions

- One common mistake is to conclude that a high *p*-value means the null hypothesis *is likely to be true*
- In reality, a high p-value tells you very little about how likely the null hypothesis is to be true!
- We'll illustrate this with a hypothetical example:
 - Suppose Steph Curry and I each shoot 5 three-point shots
 - I make 2/5 and he makes 5/5
 - Under the null hypothesis that we are equally good at three-point shooting, the probability (*p*-value) of a result this extreme is 0.17
 - Do these results justify the conclusion that Steph Curry and I are equally good shooters?

While that hypothetical example illustrates the problem, but maybe you're thinking that no makes conclusions like that in real life...

Unfortunately, it happens all the time:

- In 2006, the Woman's Health Initiative found that low-fat diets are associated with reduced breast cancer risk with a *p*-value of 0.07
- The NY Times ran the headline: "Study Finds Lowfat Diets Won't Stop Cancer or Heart Disease"
- The article described the study's results as: "The death knell for the belief that reducing the percentage of fat in the diet is important for health"

- As a brief aside, the statistical testing framework is not designed to "prove" a null hypothesis
- The closest you might come to "proving the null hypothesis" would be finding a confidence interval whose range is very narrow around the null value
 - Such an interval would suggest that only values which are extremely close to the null hypothesis are plausible

- Another common mistake is mistaking a statistically significant result for a clinically significant result
 - Statistical significance simply suggests that the observed differences are unlikely to be due to random chance
 - It doesn't mean that the observed differences are of any practical importance

Statistical vs. Clinical Significance

- In the 1980s pharmaceutical company AstraZeneca developed an incredibly successful heartburn medication *Prilosec*
- The FDA patent for Prilosec ran out in 2001, prompting AstraZeneca to try to replace Prilosec with a new drug Nexium
- The active ingredients of these drugs are:
 - Omeprazole (Prilosec)
 - Esomeprazole (Nexium)
- Without getting in to the chemistry, Omeprazole is a 50-50 mix of active and inactive isomers, while Esomeprazole only contains active "S" isomers
- Thus, taking the same amount of Nexium provides twice the effective dose of the active isomer

Nexium vs. Prilosec

- With this "modification", AstraZeneca showed that Nexium had a healing rate of 90% for erosive esophagitis, while Prilosec only had a 87% success rate
- Because the sample size of the trial was large (nearly 6,000), the difference was statistically significant with a *p*-value well below 0.05
- This led the FDA to approve Nexium, while AstraZeneca spent hundreds of millions of dollars marketing the drug to patients and doctors as a state-of-the-art improvement over Prilosec under the slogan: "better is better"
- The marketing campaign worked, AstraZeneca has since made over 47 billion dollars from Nexium

Nexium vs. Prilosec

- Practically speaking, the success rate of the two drugs was roughly the same, it was the large sample size that led to a statistically significant difference
- The 95% confidence interval for the factor by Nexium improved the healing rate was (1.02, 1.06)
- Furthermore, the small observed difference is almost surely due to Nexium containing more of the active isomer, not a groundbreaking development
- This is an example of when statistical hypothesis testing can go wrong
 - Statistical testing doesn't measure practical importance
 - Statistical testing needs to be informed by other sources of scientific knowledge

Putting it all together

An important part of this class is translating the results of statistical test to a meaningful conclusion. Below are several examples ranging from "Really Really Bad", "Really Bad", "Bad", "Okay", "Good", and "Really Good". With your group try to classify each statement:

- 1. p < 0.05 so we reject the null hypothesis
- 2. p = 0.01, indicating strong evidence that Nexium is more effective than Prilosec at treating heartburn
- 3. The study failed to reject the hypothesis that diet isn't associated with breast cancer risk
- 4. The study provided borderline evidence (p = 0.07) that low-fat diets reduce breast cancer risk, it is possible that diet has no effect, but it is also possible that low-fat diets have a small protective effect
- 5. The study rejected the hypothesis that Nexium and Prilosec are equally good
- 6. p > 0.05, so the null hypothesis is likely true

Putting it all together

- 1. p < 0.05 so we reject the null hypothesis **Really Bad**
- 2. p = 0.01, indicating strong evidence that Nexium is more effective than Prilosec at treating heartburn **Good**
- 3. The study failed to reject the hypothesis that diet isn't associated with breast cancer risk **Okay**
- 4. The study provided borderline evidence (p = 0.07) that low-fat diets reduce breast cancer risk, it is possible that diet has no effect but it is also possible that low-fat diets have a small protective effect **Really Good**
- 5. The study rejected the hypothesis that Nexium and Prilosec are equally good **Bad**
- 6. p > 0.05, so the null hypothesis is probably true **Really Really Bad**

- So far we've seen how to determine the *p*-value when given the null distribution
- In theory, the null distribution not only requires repeated sampling but also for the null hypothesis to be true... so how do we estimate it?
- In our next lab we will learn about randomization approaches aimed at simulating the null distribution

Right now you should...

- 1. Understand null hypotheses and how *p*-values measure the evidence against the null
- 2. Understand how randomization allows us to replicate the study/experiment under the null hypothesis
- 3. Know how to perform a randomization test using StatKey
- 4. Be aware of *p*-value misconceptions

These notes cover Sections 4.1 - 4.3 of the textbook, I encourage you to read through those sections and their examples